Brief: Pfizer Opts In To LianBio Rights To Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir

LianBio

19/12/2022 12:26

Dec 19 (Reuters) - Pfizer Inc  PFE.N :
    * PFIZER OPTS IN TO LIANBIO RIGHTS TO RESPIRATORY SYNCYTIAL
VIRUS
THERAPEUTIC CANDIDATE SISUNATOVIR IN MAINLAND CHINA, HONG KONG,
MACAU, AND SINGAPORE
    * PFIZER INC - PFIZER WILL NOW LEAD ALL DEVELOPMENT AND
COMMERCIALIZATION ACTIVITIES IN MAINLAND CHINA, HONG KONG,
MACAU, AND SINGAPORE
    * PFIZER INC - LIANBIO WILL RECEIVE A $20 MILLION UPFRONT
PAYMENT
    * PFIZER - LIANBIO ELIGIBLE TO GET UP TO $135 MILLION IN
POTENTIAL
MILESTONE PAYMENTS AND TIERED LOW SINGLE DIGIT PERCENT OF NET
SALES IN TERRITORIES

Source text for Eikon:  ID:nGNX21Z1w2 
Further company coverage:  PFE.N 
 ((Reuters.Briefs@thomsonreuters.com;))